Accessibility Menu
Alpha Cognition logo

Alpha Cognition(NASDAQ) ACOG

Current Price$7.90
Market Cap$127.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-56%
5 Year-56%
1 Year-18%
1 Month+25%
Alpha Cognition last closing stock price
MetricPriceDate
Last closeUSD 8.232026-07-23
Alpha Cognition stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.44%USD 8.352026-07-16
1 month+25.17%USD 6.582026-06-23
3 month+20.06%USD 6.862026-04-24
Year to date+26.62%USD 6.502025-12-31
1 year-17.62%USD 9.992025-07-23
3 year+18.89%USD 6.922023-07-24
5 year-56.28%USD 18.832021-07-20
Since inception-56.11%USD 18.752021-06-28

Alpha Cognition Financials at a Glance

Market Cap

$127.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$10.83M

Net Income (TTM)

-$25.14M

EPS (TTM)

-$1.37

P/E Ratio

-6.00

Dividend

$0.00

Beta (Volatility)

0.50 (Low)

Price

$7.90

Volume

29,283

Open

$8.23

Previous Close

$7.90

Daily Range

$7.60 - $8.48

52-Week Range

$4.50 - $10.15

Estimated Earnings Date

Aug 13, 2026

ACOG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alpha Cognition

Alpha Cognition develops medicines for brain diseases like Alzheimer’s and ALS.

Its main drug, ZUNVEYL, is indicated for the treatment of mild-to-moderate Alzheimer's disease.

The company develops treatments intended to improve cognitive and functional symptoms in patients with neurodegenerative diseases.

Brainy Business: Products and Services

  • ZUNVEYL (Alzheimer’s drug): Oral tablet for mild-to-moderate Alzheimer’s disease.
  • Licensing Revenue: Income from licensing ZUNVEYL rights abroad; 33.5% of 2025 revenue; partners with companies in Asia-Pacific.
  • Pipeline Therapies: Early-stage drugs for ALS and other brain diseases; not yet generating revenue; targets patients with severe neurological conditions.
  • Combination Therapies: Pre-clinical products combining ZUNVEYL with other drugs for advanced Alzheimer’s; not yet on the market.
  • Sublingual Formulation: Under development for patients who have trouble swallowing pills; not yet commercialized.

Growth Spurts: Expansion Moves

  • Launched ZUNVEYL in the U.S. in March 2025, entering the commercial market.
  • Signed exclusive licensing deal with CMS International Development and Management Limited in 2025 for Asia-Pacific rights.
  • Expanded sales team in 2025 to target long-term care facilities and nursing homes.
  • Set up manufacturing partnerships in Taiwan and the U.S. in 2025 to support product supply.
  • Raised $35 million in October 2025 and $50 million in November 2024 through public offerings.

What Makes Alpha Cognition Stand Out

Alpha Cognition focuses on brain health, targeting underserved patient groups. Its main drug uses a delayed-release formula to reduce side effects. The company’s licensing and manufacturing partnerships support global reach and supply stability.

Five Things You Need to Know

  • Revenue was $10.2 million in 2025, up from $0 in 2024.
  • Net loss was $20.7 million in 2025, up 40% from 2024.
  • Cash and cash equivalents reached $66 million at year-end 2025, up 36% from 2024.
  • Operating expenses rose 174% to $32.9 million in 2025.

Bottom Line

Alpha Cognition shifted from research to commercial sales in 2025, focusing on Alzheimer’s treatment. The company is expanding globally while managing high costs and operational risks.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

71

CEO

Michael E. McFadden

Website

www.alphacognition.com

Headquarters

Grapevine, TX V6C 2T8, US

ACOG Financials

Key Financial Metrics (TTM)

Gross Margin

84.42%

Operating Margin

-249.97%

Net Income Margin

-232.24%

Return on Equity

-54.13%

Return on Capital

-36.24%

Return on Assets

-36.31%

Earnings Yield

-16.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$127.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

15.53M

Volume

29.28K

Avg. Volume

55.06K

Financials (TTM)

Gross Profit

$9.14M

Operating Income

-$27.06M

EBITDA

-$26.96M

Operating Cash Flow

-$30.19M

Capital Expenditure

-$219.78K

Free Cash Flow

-$30.41M

Cash & ST Invst.

$54.25M

Total Debt

$0.00

Alpha Cognition Performance Analysis

Alpha Cognition annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 10,220,275N/A
Alpha Cognition sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-43.4%
Q32025-09-3071.4%
Q42025-12-31-1.7%
Q12026-03-3126.5%
Alpha Cognition annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.44-51.5%
20232023-12-31USD -3.65-17.8%
20242024-12-31USD -2.04-44.1%
20252025-12-31USD -1.18-42.2%
Alpha Cognition sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-400.0%
Q32025-09-3087.7%
Q42025-12-31-287.5%
Q12026-03-31-3.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$3.53M

+20.7%

Gross Profit

$3.26M

+55.9%

Gross Margin

92.31%

N/A

Market Cap

$127.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.80M

N/A

Employees

71

N/A

Net Income

-$6.48M

-222.8%

EBITDA

-$8.07M

-306.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$54.25M

+19.2%

Total Debt

$0.00

N/A

Accounts Receivable

$3.58M

+488.0%

Inventory

$6.04M

+584.2%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-36.31%

N/A

Return on Invested Capital

-42.40%

N/A

Free Cash Flow

-$11.80M

-459.8%

Operating Cash Flow

-$11.80M

-477.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NOEMCO2 Energy Transition Corp.
$11.02+3.77%
CHPGChampionsGate Acquisition Corporation Class A Ordinary Share
$10.44+0.19%
FGBIFirst Guaranty Bancshares, Inc.
$9.29+0.32%
DTSQDT Cloud Star Acquisition Corporation
$11.35+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About ACOG

What is the current price of Alpha Cognition?

Alpha Cognition is trading at $7.90 per share.

What is the 52-week range for Alpha Cognition?

Over the past 52 weeks, Alpha Cognition has traded between $4.50 and $10.15.

How much debt does Alpha Cognition have?

As of the most recent reporting period, Alpha Cognition reported total debt of $0.00.

How much cash does Alpha Cognition have on hand?

Alpha Cognition reported $54.31M in cash and cash equivalents in its most recent financial results.

What is Alpha Cognition’s dividend yield?

Alpha Cognition does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services